Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Gilead Sciences, Inc. — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.6, while Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | GILD | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $155.80 |
52-Week Low | $24.83 | $110.56 |
Market Cap | — | $168.35B |
Enterprise Value | — | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
